Apocell Inc. | Date: 2015-04-02
The present invention provides a new method for accurately identifying DEP cross-over frequencies of one or more particles in a sample, and quickly and efficiently conveying that information to assist in the separation, e.g., DEP separation, or analysis of the one of more particles under examination or investigation. The present invention also provides an apparatus and method for monitoring the dielectrophoretic response of one or more particles and determining the DEP cross-over frequency of particles of interest.
News Article | May 1, 2017
— According to Stratistics MRC, the Global Circulating Tumor Cells Market is accounted for $4.41 billion in 2015 and is expected to reach $17.96 billion by 2022 growing at a CAGR of 19.2 % from 2015 to 2022. The rising demand for high Benefit-Cost Ratio (BCR) associated with CTCs prognostic technology is the major factor boosting the market growth. Furthermore, advancements in biomedical imaging and bioengineering technology are some of the key factors driving the market. However, high cost associated with the diagnosing and reluctance among people towards adopting highly developed prognostic technologies inhibit the market growth. The recent trends in global Circulating Tumor Cells are strengthening distribution network of CTCs prognostic technologies in emerging economies and the technical advancement of CTCs-based customized medicines. Tumor cell detection is the foremost product segment primarily due to the advantages related with therapeutic monitoring and high procedure prices. North America region is expected to witness highest growth rate during the forecast period due to increasing demand in number of research projects. In addition, the U.S. Government also supports research by funding various institutes, which grant research funds. Some of the key players in the market include Adnagen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept Inc., Biofluidica, Canopus Biosciences, CellTraffix Inc., Clearbridge BioMedics, Creatv Microtech Inc., Cynvenio Biosystems Inc. , Epic Biosciences, Fluxion Biosciences., Greiner Bio-One GmbH, Ikonisys Inc., IV Diagnostics Inc., Janssen Diagnostics, Miltenyi Biotech and Nanostring Technologies Inc. Regions Covered: North America US Canada Mexico Europe Germany France Italy UK Spain Rest of Europe Asia Pacific Japan China India Australia New Zealand Rest of Asia Pacific Rest of the World Middle East Brazil Argentina South Africa Egypt Major Points From Table Of Contents: Executive Summary Preface Market Trend Analysis Porters Five Force Analysis Key Developments Company Profiling About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/circulating-tumor-cells-global-market-outlook-2015-2022
Gupta V.,Apocell Inc. |
Jafferji I.,Apocell Inc. |
Garza M.,Apocell Inc. |
Melnikova V.O.,Apocell Inc. |
And 3 more authors.
Biomicrofluidics | Year: 2012
Isolation and enumeration of circulating tumor cells (CTCs) are used to monitor metastatic disease progression and guide cancer therapy. However, currently available technologies are limited to cells expressing specific cell surface markers, such as epithelial cell adhesion molecule (EpCAM) or have limited specificity because they are based on cell size alone. We developed a device, ApoStream™ that overcomes these limitations by exploiting differences in the biophysical characteristics between cancer cells and normal, healthy blood cells to capture CTCs using dielectrophoretic technology in a microfluidic flow chamber. Further, the system overcomes throughput limitations by operating in continuous mode for efficient isolation and enrichment of CTCs from blood. The performance of the device was optimized using a design of experiment approach for key operating parameters such as frequency, voltage and flow rates, and buffer formulations. Cell spiking studies were conducted using SKOV3 or MDA-MB-231 cell lines that have a high and low expression level of EpCAM, respectively, to demonstrate linearity and precision of recovery independent of EpCAM receptor levels. The average recovery of SKOV3 and MDA-MB-231 cancer cells spiked into approximately 12 × 106 peripheral blood mononuclear cells obtained from 7.5 ml normal human donor blood was 75.4% ± 3.1% (n = 12) and 71.2% ± 1.6% (n = 6), respectively. The intra-day and inter-day precision coefficients of variation of the device were both less than 3%. Linear regression analysis yielded a correlation coefficient (R2) of more than 0.99 for a spiking range of 4-2600 cells. The viability of MDA-MB-231 cancer cells captured with ApoStream was greater than 97.1% and there was no difference in cell growth up to 7 days in culture compared to controls. The ApoStream device demonstrated high precision and linearity of recovery of viable cancer cells independent of their EpCAM expression level. Isolation and enrichment of viable cancer cells from ApoStream enables molecular characterization of CTCs from a wide range of cancer types. © 2012 American Institute of Physics.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 999.75K | Year: 2013
Apocell Inc. | Date: 2010-06-04
Apocell Inc. | Date: 2011-06-01
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 198.81K | Year: 2011
Rare cell sublets in peripheral blood, such as circulating tumor cells (CTCs) has been used as biomarkers for cancer progression. In addition, growing evidence suggests that CTC isolation from a blood sample may allow reliable early detection and molecularcharacterization of cancer at diagnosis or relapse and provide a minimally-invasive method to guide and monitor the results of cancer therapy in cancer patients. Our goal is to commercialize a cost effective point of care device capable of isolating viable CTCs from a wide variety of cancers, for which proof of concept has been achieved in a research setting. For this Phase I proposal, we aim (1) to demonstrate the device feasibility for antibody independent isolation of viable CTCs, (2) to compare performance against the current FDA approved, state-of-the-art CTC isolation technology,and (3) characterize system performance. With the introduction of this technology, CTCs can be isolated from all metastatis cancers and provide a pre-screen diagnostic tool for cancer patients in a point of care setting. Also, unpurterbed and viable state of CTCs will allow systematic biological analysis of individual cells, permitting a personalized approach to cancer therapy.
Apocell Inc. | Date: 2014-08-28
Methods and apparatuses for target particle separation and isolation are disclosed. The apparatuses are flow chambers that include an infusion port configured to introduce a sample, and an elution flow port configured to receive an elution buffer. The flow chamber also includes an electrode coupled to a floor of the flow chamber, wherein the electrode includes at least a first zone with a first inter-electrode pitch and a second zone with a second inter-electrode pitch. The first zone generates a first electric field and the second zone generates a second electric field of a different magnitude than the first electric field when an electric signal is applied. The first electric field and the second electric field separate the target particle from the fluidic suspension via dielectrophoresis. The flow chamber also includes a waste disposal port that discharges the waste material, and a collection port configured that collects a target particle enriched sample.
News Article | December 24, 2013
In less than a decade, the Houston-based research services company ApoCell has made a name for itself amid the developing life sciences industry in Texas. Based on its rapid revenue increases, ApoCell has been named to the Inc 5000 list of fastest-growing private US companies for the past three years. ApoCell has now set a new goal that could be seen as a kind of Holy Grail in molecular diagnostics. By 2016, ApoCell hopes to begin selling benchtop devices that could alert doctors when cancer drugs have stopped working for an individual patient, and might also help reveal which drugs are most likely to restore control of tumor growth. ApoCell is one of several companies developing instruments that can capture tumor cells circulating in the blood of cancer patients. The number of these cells alone is a valuable clue to the severity of the disease, and the effectiveness of drugs. But in addition, once these rare cells have been isolated from the blood cells by the company’s ApoStream device, they can be tested to provide a snapshot of the signature molecular traits of the diseased cells. Already this kind of molecular analysis, performed on cells from tumor biopsies, can often point to the drugs best tailored to attack particular cancer subtypes. But biopsies can be invasive and painful. The hope is that tumor cells could be routinely extracted instead from patient blood samples with the help of analyzers like ApoCell’s. This “liquid biopsy” could be repeated more often than a traditional biopsy, to track a patient’s tumor cell population as it evolves and develops resistance to initial drug treatments. “The testing technologies used in tumor biopsies are applied to rare cells,” says ApoCell CEO Darren Davis. It was ApoCell’s clients who, in 2007, sent the company on the hunt for a new way to pluck tumor cells out of the blood, leading to the development of ApoStream, Davis says. The company, which Davis founded in 2004, had quickly become profitable as a provider of tests such as genetic analysis and cancer biomarker detection for drug developers, he says. ApoCell was also offering a commercial test for blood levels of circulating tumor cells—the CellSearch system, marketed by Johnson & Johnson unit Janssen Diagnostics of Raritan, NJ. But pharmaceutical companies asked ApoCell to look for another method that would expand the range of information that could be gleaned, beyond the limits of the CellSearch product. CellSearch delivers a total count of circulating tumor cells, and is FDA-cleared for clinical use in three major cancers—breast cancer, prostate cancer, and colorectal cancer. A rise in the mere numbers of such cells points to a poor prognosis in these cancer types, according to studies using the CellSearch system. A higher blood count of tumor cells indicates that … Next Page »